Vazquez MA, et al.; ICD-Pieces Study Group. Pragmatic trial of hospitalization rate in chronic kidney disease. N Engl J Med 2024; 390:1196–1206. doi: 10.1056/NEJMoa2311708
Jefferies JL, et al. A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm. Orphanet J Rare Dis 2021; 16:518. doi: 10.1186/s13023-021-02150-3
Solanki KV, et al. The phenotypic spectrum of COL4A3 heterozygotes. Kidney Int Rep 2023; 8:2088–2099. doi: 10.1016/j.ekir.2023.07.010
Puurunen M, et al. Twenty-four-hour urine oxalate and risk of chronic kidney disease. Nephrol Dial Transplant 2024; 39:788–794. doi: 10.1093/ndt/gfad221
AWAK Technologies Pte Ltd. AWAK Technologies announces FDA breakthrough device designation for their artificial intelligence enabled kidney disease prediction tool. PR Newswire. November 27, 2023. Accessed June 24, 2024. https://www.prnewswire.com/news-releases/awak-technologies-announces-fda-breakthrough-device-designation-for-their-artificial-intelligence-enabled-kidney-disease-prediction-tool-301997423.html
Gudelunas MK, et al. Low perfusion and missed diagnosis of hypoxemia by pulse oximetry in darkly pigmented skin: A prospective study. Anesth Analg 2024; 138:552–561. doi: 10.1213/ANE.0000000000006755